Form 8-K - Current report:
SEC Accession No. 0001193125-25-105825
Filing Date
2025-04-30
Accepted
2025-04-30 08:15:22
Documents
15
Period of Report
2025-04-30
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d935544d8k.htm   iXBRL 8-K 27626
2 EX-99.1 d935544dex991.htm EX-99.1 20383
6 GRAPHIC g935544g0430071924963.jpg GRAPHIC 2596
  Complete submission text file 0001193125-25-105825.txt   182192

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA jagx-20250430.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20250430_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20250430_pre.xml EX-101.PRE 11279
17 EXTRACTED XBRL INSTANCE DOCUMENT d935544d8k_htm.xml XML 3636
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 25891137
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)